What 49 studies reveal about diet and Crohn’s disease
A new scoping review mapped 49 studies of dietary interventions in Crohn's disease and ulcerative colitis. It found no single winning diet, but a consistent pattern across very different named diets: cut processed food and added sugar, favor whole foods. A head to head trial also found a simpler Mediterranean diet matched a stricter elimination diet for symptom remission.
If you live with Crohn's disease or ulcerative colitis, you have almost certainly already tried changing what you eat, and you have probably ended up more confused than when you started. Every corner of the internet pushes a different diet as the fix, from strict elimination protocols to Mediterranean-style eating, each with its own testimonials attached. A new scoping review in Therapeutic Advances in Gastroenterology set out to map, not rank, what has actually been studied, pulling together 49 studies of dietary interventions in inflammatory bowel disease published between 2008 and 2025. The clearest finding is not about crowning a winner. It is about what several very different diets quietly agreed on.
Key takeaways
- A 49-study scoping review found no single "best" diet for Crohn's disease or ulcerative colitis, just a shared pattern across diets: less processed food and added sugar, more whole foods.
- In the one head-to-head trial in the review, a Mediterranean diet matched a stricter elimination diet for symptom remission (43.5% versus 46.5%), a difference too small to call significant.
- People often reported feeling better before their inflammatory bloodwork caught up, a mismatch the review's authors flagged repeatedly.
- This is a map of existing research, not a ranking or a treatment guideline. Any diet change is worth discussing with your doctor or a registered dietitian first.
Scoping Review Maps 49 Studies Of Diet In IBD
A scoping review (a study that maps and summarizes existing research on a topic rather than statistically pooling the results into one combined number) analyzed 49 studies of dietary interventions in adults with Crohn's disease and ulcerative colitis, published from 2008 to 2025. Researchers led by Ingridsdotter and colleagues, publishing in Therapeutic Advances in Gastroenterology, used a heatmap analysis (a visual method for spotting patterns that repeat across many studies) to compare the composition of every named diet in the review, including the Mediterranean diet, IgG/IgG4-guided elimination diets, and the Crohn's Disease Exclusion Diet (CDED), the three most-studied approaches. Despite covering wildly different named protocols, the diets that showed benefit converged on the same two moves: cutting processed foods and added sugar, and emphasizing whole foods such as fruits, vegetables, and unsaturated fats.
Why Crohn's And Ulcerative Colitis Patients Should Care
Inflammatory bowel disease (IBD, the umbrella term for Crohn's disease and ulcerative colitis, both driven by chronic immune-related inflammation in the gut) affects people who often feel they have little control over their condition between flares and doctor visits, and diet is one of the few levers they can pull themselves. That is exactly why the space is so crowded with competing claims. The National Institute of Diabetes and Digestive and Kidney Diseases and the Crohn's & Colitis Foundation both note that no single eating plan has been proven to control IBD for everyone. This review does not change that. What it offers instead is the first attempt to organize the scattered diet literature into one picture, rather than adding one more single-diet study to the pile.
Inside The 49-Study Review's Design
The review followed PRISMA-ScR methodology (a standardized checklist for conducting and reporting scoping reviews) and systematically searched PubMed, CINAHL, Scopus, and Web of Science through January 2025, with an update in May 2026, plus grey literature. That search turned up 49 eligible studies: 36 primary intervention studies (a mix of randomized controlled trials and non-randomized studies), 8 reviews, and 5 case studies, done predominantly in North America (19 studies) and Europe (16 studies). It is worth being precise about what a scoping review does and does not do: it maps the shape of existing evidence, but by design it does not appraise the quality of individual studies or pool their results into a single combined effect size the way a meta-analysis would.
What The Convergence Finding Means For Your Plate
The best-supported takeaway is not a specific diet, it is the pattern shared across nearly all of them: cutting processed food and added sugar while favoring whole foods was common to the diets that showed benefit, regardless of what each one was named. Beyond that convergence, a few individual results stand out. In the DINE-CD trial (n=92), a Mediterranean diet produced a 43.5% symptomatic remission rate at 6 weeks, statistically indistinguishable from the 46.5% seen with the far more restrictive Specific Carbohydrate Diet. In other words, a simpler, more liveable diet performed as well as a stricter one. Separately, a randomized pilot trial of the Crohn's Disease Exclusion Diet (n=40) reported that the median endoscopic disease score fell 72.8% by week 24, alongside a significant drop in C-reactive protein (CRP, a blood marker of inflammation). And a separate trial comparing low-meat to high-meat diets (n=213) found no significant difference in relapse rates, challenging the common assumption that meat itself is the problem. None of this makes any single diet a proven treatment. The review's authors themselves call for larger, more standardized trials before drawing firm conclusions, so the practical takeaway is to raise these findings with your gastroenterologist or a dietitian before making a major change, especially during an active flare.
Small Trials And A Symptom-Biomarker Mismatch
The underlying evidence is thinner than 49 studies might suggest, because individual trial sizes ranged from just 7 to 213 participants, with many enrolling fewer than 30 people, and diet definitions, comparison groups, and outcome measures varied so much that even studies using the same diet name were not always comparable. Many of the 36 primary studies were non-randomized or uncontrolled, and most had short follow-up periods. A recurring pattern the authors flagged repeatedly across studies is arguably the most clinically important limitation: patient-reported symptoms and quality of life improved more consistently than objective inflammatory biomarkers like CRP and fecal calprotectin (a stool protein that rises with gut inflammation). That disconnect matters because feeling better is not the same as the gut actually healing. Inflammation can keep smoldering even after symptoms ease, which is why doctors track blood and stool markers alongside how a patient feels, not one or the other.
Larger, Standardized Trials Are The Next Step
The review's authors conclude that several diets look viable for IBD, with the Mediterranean diet and its shared whole-food principles standing out as the best-supported, safest option that also aligns with existing dietary guidelines, though that is their interpretation of the mapped evidence rather than a statistically pooled result. Their call to action is for future trials to use larger sample sizes and standardized outcome measures so results can actually be compared across studies, rather than each diet being tested in isolation with its own definitions. No specific timeline for that follow-up research is given.
Common Questions
Does diet cure Crohn's disease or ulcerative colitis? No. No diet studied in this review has been proven to cure IBD or replace medical treatment. Several diets showed symptom improvement in small trials, but the review's own authors call for larger studies before any diet can be considered an established treatment.
Is the Mediterranean diet as good as stricter diets like the Specific Carbohydrate Diet for Crohn's? In the one head-to-head trial included in the review, the Mediterranean diet and the Specific Carbohydrate Diet produced statistically similar remission rates at 6 weeks, 43.5% versus 46.5%, suggesting the simpler diet was not meaningfully worse.
If I feel better after changing my diet, does that mean my inflammation is under control? Not necessarily. The review found that patient-reported symptom improvement often did not match changes in inflammatory blood and stool markers, so it is worth discussing objective testing, such as CRP or fecal calprotectin, with your doctor even if you feel better.
What is the one dietary pattern that shows up across most of the diets studied? Cutting processed foods and added sugar while emphasizing whole foods, fruits, vegetables, and unsaturated fats, a pattern the review found in common across otherwise very different named diets.
Evidence Rating
EMERGING — 76/100
Caveats
- A scoping review maps evidence but does not perform quality appraisal or pooled meta-analysis
- Underlying trials mostly small (n=7-213) and heterogeneous
- Patient-reported improvement often did not match objective inflammatory biomarkers (CRP/calprotectin), a mismatch the authors flag repeatedly
A scoping review mapping 49 mostly small, heterogeneous trials of dietary interventions in Crohn’s and ulcerative colitis; it summarizes patterns across studies rather than pooling them statistically, and symptom improvement did not always track with inflammatory biomarker changes.
References
- Josephine Ingridsdotter, Vedrana Vejzovic, Eva Elmerstig, Klas Sjöberg (2026). Multiple paths to health: A scoping review of dietary interventions for adults with Crohn’s disease and ulcerative colitis. Therapeutic Advances in Gastroenterology. https://doi.org/10.1177/17562848261479366
- Eating, Diet, & Nutrition for Crohn's Disease. NIH. https://www.niddk.nih.gov/health-information/digestive-diseases/crohns-disease/eating-diet-nutrition
- A Randomized Trial Comparing the Specific Carbohydrate Diet to a Mediterranean Diet in Adults With Crohn's Disease. NIH. https://pubmed.ncbi.nlm.nih.gov/34052278/
- The Crohn's disease exclusion diet for induction and maintenance of remission in adults with mild-to-moderate Crohn's disease (CDED-AD). NIH. https://pubmed.ncbi.nlm.nih.gov/34739863/